Process knowledge not captured during pilot scale – how to ensure smooth tech transfer


“`html






Published on 21/01/2026

Addressing Uncaptured Process Knowledge During Pilot Scale for Effective Tech Transfer

In the pharmaceutical manufacturing environment, capturing comprehensive process knowledge during the pilot scale can often be overlooked, leading to challenges during the tech transfer to full-scale production. This investigation will enable professionals to recognize symptoms, identify root causes, and implement corrective and preventive actions (CAPA) that foster smooth tech transfers and maintain GMP compliance. By following structured workflows and analytical methods, you’ll be equipped to ensure that your process knowledge is accurately captured and utilized.

Through this article, we will outline a systematic approach for investigating instances where process knowledge may have been insufficiently captured during pilot scale operations. This will empower stakeholders in manufacturing, quality control, and validation to craft effective responses following best practices and regulatory expectations.

Symptoms/Signals on the

Floor or in the Lab

Identifying signs that process knowledge is not fully captured during pilot scale is critical. Some common symptoms include:

  • Deviation Reports: Increased frequency of deviation reports related to failures during scale-up.
  • Out of Specification (OOS) Results: Instances where analytical results do not meet established specifications.
  • Manufacturing Delays: Unexplained delays during batch processing or transfers.
  • Inconsistent Product Quality: Variability in product attributes that was not observed in pilot batches.
  • Lack of Clarity in Documentation: Incomplete or vague records from pilot studies hindering replicability.

Recognizing these symptoms early can help in determining whether process knowledge gaps exist, prompting further investigation to categorize failures appropriately.

Likely Causes

When investigating uncaptured process knowledge, it is beneficial to categorize potential causes systematically. The following framework—Materials, Method, Machine, Man, Measurement, Environment—can assist in exploring each dimension of failure:

Category Likely Cause
Materials Insufficient characterization of raw materials leading to variability.
Method Pilot methods not adequately defined or required parameters not captured.
Machine Equipment incapable of replicating pilot environment at scale.
Man Insufficient training or knowledge of operators regarding new processes.
Measurement Inadequate calibration of measurement tools leading to data integrity issues.
Environment Changes in ambient conditions not documented or controlled during pilot runs.

By considering these categories, a more focused approach to identifying the source of the issues can be taken.

Immediate Containment Actions (first 60 minutes)

In the first hour of identifying potential knowledge gaps, immediate action is crucial. The following containment strategies should be deployed:

  • Identify and Segregate Affected Batches: Quickly isolate any affected batches or materials to prevent broader impact.
  • Initiate Preliminary Investigation: Activate a cross-functional team to discuss initial findings and potential triggers.
  • Notify Quality Assurance: Inform QA personnel to ensure documentation aligns with compliance standards.
  • Document Findings: Record all observations and immediate actions taken to create a traceable history of responses.

By acting decisively in the face of potential failures, teams can mitigate immediate risks while preparing for a more thorough investigation.

Investigation Workflow (data to collect + how to interpret)

A structured investigation workflow will aid in systematically addressing the knowledge gaps. The following steps outline the essential data collection methods:

  • Gather Historical Data: Collect batch records, manufacturing logs, and quality control data from pilot runs and subsequent production.
  • Conduct Interviews: Interview personnel involved in pilot scale operations to gain insights on methods, challenges faced, and decision-making processes.
  • Analyze Deviations: Review all deviation reports related to the batches in question to identify trends or common factors.
  • Review Analytical Test Methods: Ensure that analytical methodologies used during pilot testing are fully documented and adhered to during scale-up.

Analysis should focus on understanding correlations between data, identifying discrepancies, and deriving patterns leading to the uncaptured process knowledge.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and When to Use Which

To establish the root cause of the failure in capturing process knowledge, several analytical tools can be employed:

  • 5-Whys: This technique is particularly useful when the problem is straightforward but requires deeper analysis to unveil underlying causes. Start by asking “why” the initial failure occurred and continue through five layers of inquiry.
  • Fishbone Diagram: This method is effective for complex problems with multiple origins, allowing teams to visually categorize causes into major categories (Materials, Methods, etc.).
  • Fault Tree Analysis: Utilize this more data-driven approach when comprehensive quantitative assessment is required, particularly in environments with established metrics for process efficacy.

By selecting the appropriate root cause analysis tool, teams can systematically address complex failures and better understand knowledge capture deficiencies.

CAPA Strategy (correction, corrective action, preventive action)

An effective CAPA strategy is essential to amend identified knowledge capture issues. The following steps outline the three essential components:

  • Correction: Address any immediate issues, such as re-running analytical tests and obtaining correct documentation for batches impacted by the knowledge gap.
  • Corrective Action: Implement changes to processes and training programs to prevent a recurrence of similar issues. For instance, conducting thorough training sessions that emphasize detailed record-keeping during pilot runs.
  • Preventive Action: Establish new protocols, including regular reviews of pilot studies to ensure that they capture sufficient data and knowledge for tech transfer.

Implementation of these components ensures that not only is the immediate issue rectified, but systemic changes also prevent future occurrences.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

Once CAPA measures are in place, robust control strategies are needed to monitor processes effectively:

  • Statistical Process Control (SPC): Implement SPC techniques to monitor process variations, helping to identify shifts in performance that may suggest recurrences of uncaptured knowledge.
  • Trending Analysis: Document and analyze trends in manufacturing and quality performance data to alert teams to potential issues before they escalate.
  • Sampling Plans: Establish stringent sampling plans at different stages of manufacturing to ensure that quality controls are actively maintained.
  • Alarms and Alerts: Set criteria for alarms to trigger when data deviates from established operating ranges, indicating a need for immediate review.
  • Verification Audits: Regularly schedule audits and verification checks to confirm that new methods are working effectively and that all knowledge gaps have been addressed.

Continuous monitoring facilitates proactive controls and allows for early detection of potential issues associated with tech transfer.

Validation / Re-qualification / Change Control Impact (when needed)

Any modifications resulting from the investigation must be evaluated for their impact on validation status and change controls. Factors to consider include:

  • Validation Requirements: Determine whether the changes necessitate a re-validation of the process, especially where procedure changes are made.
  • Re-qualification Needs: Assess if equipment or systems used in pilot and production phases require re-qualification based on procedural adjustments.
  • Change Control Procedures: Ensure that thorough documentation follows all changes made as a result of the CAPA process, maintaining compliance with regulatory expectations.

Engaging with validation experts early in the investigation can streamline this aspect, keeping in alignment with frameworks such as ICH Q7 and Q10 guidelines.

Inspection Readiness: What Evidence to Show

When preparing for regulatory inspections, maintaining a clear evidential trail is vital. Key records to present include:

  • Deviation Logs: Keep a detailed account of all deviations captured during the pilot and production processes.
  • CAPA Documentation: Ensure that all CAPA actions undertaken are documented comprehensively, highlighting problem-solving workflows.
  • Batch Records: Demonstrate comprehensive batch records reflecting compliance with established protocols.
  • Training Records: Show evidence of training sessions conducted for relevant personnel on new procedures or methods.
  • Quality Control Reports: Present all quality control test results leading up to the incident, showcasing diligent efforts to capture knowledge accurately.

Inspection readiness hinges on not just having the right documents but ensuring that they illustrate a systematic approach to process knowledge capture.

FAQs

What is a pilot scale in pharmaceutical manufacturing?

A pilot scale refers to an intermediate stage of production where processes are tested on a smaller scale before full-scale manufacturing to identify and resolve potential issues.

Why is data integrity critical during tech transfer?

Data integrity ensures that the information captured during pilot runs is reliable and accurate, providing a dependable basis for future production processes.

How can SPC help in monitoring manufacturing processes?

SPC helps track process variation over time, enabling early detection of deviations that could indicate underlying knowledge capture issues.

What regulatory bodies oversee pharmaceutical manufacturing in the US, UK, and EU?

In the US, the FDA governs pharmaceutical manufacturing. The EMA oversees operations within the EU, while the MHRA regulates in the UK.

How often should CAPA efforts be reviewed?

CAPA efforts should be reviewed regularly, at minimum biannually, or whenever a significant deviation occurs that may affect the overall quality of the product.

Related Reads

Are re-qualifications necessary after a CAPA?

Re-qualifications may be necessary depending on the nature and extent of the changes made during the CAPA process, especially regarding equipment or processes.

What impact do changes have on lifecycle management?

Changes stemming from CAPA efforts must be documented within lifecycle management processes to ensure compliance and traceability throughout the product’s development stages.

How should companies prepare for inspections following a deviation?

Companies should ensure that all documentation is complete, accurate, and accessible, demonstrating effective measures taken in response to the deviation.

What should be included in a corrective action report?

A corrective action report should outline the deviation, root cause analysis, actions taken, and measures put in place to prevent recurrence.

How can training be improved to avoid knowledge capture issues?

Regular and comprehensive training sessions that emphasize the importance of detailed documentation and process adherence can improve knowledge capture significantly.

What are the common pitfalls during tech transfer?

Common pitfalls include inadequate documentation, insufficient training, lack of process understanding, and unrealistic timelines that overlook critical data requirements.

Why is it important to document CAPA processes?

Documenting CAPA processes is vital for demonstrating compliance, learning from failures, ensuring transparency, and facilitating continuous improvement within the organization.

Pharma Tip:  Design space poorly justified during comparability assessment – how to ensure smooth tech transfer